Universal Beteiligungs und Servicegesellschaft mbH Makes New $2.34 Million Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH made a significant investment of $2.34 million in Revolution Medicines, Inc., acquiring 66,251 shares of the company's stock.
• Revolution Medicines reported a loss of $1.13 EPS for the last quarter, slightly missing analysts' consensus estimates, with expectations of a -3.49 EPS for the current fiscal year.
• Despite recent losses, eleven analysts have rated Revolution Medicines with a "buy," with an average target price of approximately $68.91.

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,251 shares of the company's stock, valued at approximately $2,343,000.

A number of other hedge funds have also recently modified their holdings of the stock. Farallon Capital Management LLC raised its stake in shares of Revolution Medicines by 17.1% during the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after buying an additional 1,931,000 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Revolution Medicines by 54.5% during the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after purchasing an additional 3,346,755 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of Revolution Medicines by 4.9% during the 4th quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock worth $347,163,000 after purchasing an additional 367,882 shares during the period. Nextech Invest Ltd. lifted its stake in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the period. Finally, FMR LLC boosted its holdings in Revolution Medicines by 14.7% during the fourth quarter. FMR LLC now owns 6,742,083 shares of the company's stock worth $294,899,000 after buying an additional 866,190 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RVMD shares. The Goldman Sachs Group began coverage on shares of Revolution Medicines in a research report on Tuesday, July 15th. They set a "buy" rating and a $65.00 price target for the company. Wedbush reiterated an "outperform" rating and set a $73.00 target price (up from $67.00) on shares of Revolution Medicines in a research report on Tuesday, June 24th. Needham & Company LLC restated a "buy" rating and issued a $57.00 price target on shares of Revolution Medicines in a research report on Tuesday, June 24th. HC Wainwright reiterated a "buy" rating and issued a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Finally, Guggenheim reiterated a "buy" rating and set a $80.00 target price on shares of Revolution Medicines in a report on Wednesday, June 25th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines presently has an average rating of "Buy" and an average target price of $68.91.

Revolution Medicines Trading Down 1.7%

RVMD traded down $0.64 on Friday, hitting $36.63. 978,549 shares of the company's stock were exchanged, compared to its average volume of 1,474,059. The firm has a market cap of $6.82 billion, a PE ratio of -9.16 and a beta of 1.16. The stock has a fifty day moving average of $38.64 and a two-hundred day moving average of $38.89. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same quarter in the previous year, the business earned ($0.70) EPS. On average, analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.